Eastern Health, Canada
Quick facts
Phase 3 pipeline
- 18F-2-fluoro-2-deoxy-D-glucose · Oncology, Neurology, Cardiology
18F-FDG is a glucose analog labeled with fluorine-18 that accumulates in metabolically active tissues and emits positrons for PET imaging detection.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Eastern Health, Canada
What is Eastern Health, Canada's pipeline?
Eastern Health, Canada has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include 18F-2-fluoro-2-deoxy-D-glucose.
Related
- Sector hub: All tracked pharma companies